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Introduction
Remarkable quantities of participant-level data and aggregate-level results are generated through clinical
research, much of which is never published or disseminated, limiting its contribution to current
knowledge and practice. Over the past ﬁve years, many leaders within the clinical research enterprise have
made bold statements and adopted policies that promote clinical research data sharing, deﬁned by the
National Academy of Medicine (formerly known as the Institute of Medicine of the U.S. National
Academy of Sciences) as the distribution of individual participant-level clinical trial data to researchers
based outside the original study investigator team to enable independent use for scientiﬁc purposes1.
Examples of organizations making recommendations to facilitate data sharing include the National
Academy of Medicine1, the World Health Organization (http://www.who.int/medicines/ebola-treatment/
data-sharing_phe/en/), the U.S. National Institutes of Health (NIH)2, the European Clinical Research
Infrastructure Network3, and the International Committee for Medical Journal Editors4, as well as both
PhRMA and EFPIA (https://www.phrma.org/press-release/joint-efpia-phrma-principles-for-responsible-
clinical-trial-data-sharing-become-effective-today), the pharmaceutical trade organizations representing
manufacturers in the United States and European Union, respectively.
Given already widespread, and still increasing, support for data sharing5–7, the challenge facing the
ﬁeld now is to develop fair and sustainable approaches for investigators to access these data and utilize
them to advance science. The Yale University Open Data Access (YODA) Project, an initiative housed
within Yale University, has been actively working to facilitate access to clinical trial data since 2013. The
purpose of this article is to provide an overview of the Project, describe key decisions that were made
when establishing data sharing policies, and suggest how our experience and the experiences of our ﬁrst
two data generator partners, Medtronic, Inc. and Johnson & Johnson, can be used to inform and thereby
enhance other ongoing or future initiatives.
Results
Overview
In 2011, the YODA Project was founded to promote data sharing among the scientiﬁc community and
develop a platform that could be used as a means of responsible data sharing8. At its inception, the
Project established an organizing mission to guide its decision-making: 1) promote the sharing of clinical
research data to advance science and improve public health and healthcare; 2) protect the rights of
research participants; 3) promote the responsible conduct of research; and 4) ensure good stewardship of
clinical research data by external investigators.
The YODA Project began as part of a partnership with Medtronic, Inc. in 2011 with two purposes9,10.
First, the Project was tasked with soliciting two independent analyses of individual participant-level data
(IPD) from all published and unpublished trials relating to its marketed product recombinant human
bone morphogenetic protein-2 (rhBMP-2). Second, following completion of these analyses in 2013, the
data were to be made available for sharing with the broader scientiﬁc community. This partnership (and
the data sharing) concluded in 2015.
In 2014, the YODA Project began a partnership with Johnson & Johnson to develop and implement a
broadly-encompassing policy to share clinical trial data for all non-Phase I interventional trials of the
company’s pharmaceutical products; data were ﬁrst made available to external investigators through this
initiative in October 201411. The scope of this agreement was expanded in 2015 to include trials of
medical device products and again in 2017 to include trials of consumer products used by health
authorities for approval from 2014 onwards; the detailed policy scope is publicly available (http://yoda.
yale.edu/policies-procedures-guide-external-investigator-access-clinical-trial-data).
In 2016, the YODA Project began a partnership with SI-BONE, Inc., a smaller medical device
company, to share clinical trial data relating to its marketed product, the iFuse sacroiliac joint fusion
implant system.
Policy Development Process
The YODA Project data sharing policy was initially established for access to Medtronic’s rhBMP-2
clinical trial data, and later for access to Johnson & Johnson’s broad portfolio of clinical trial data. The
policy established the procedures external investigators were required to follow to gain access to data for
independent scientiﬁc examination (see Fig. 1 for illustration). Development was iterative and informed
by the following:
● Input from partnering companies that have generated the clinical trial data;
● Input from the YODA Project’s Steering Committee, an independent group of leaders in the ﬁelds of
clinical research and biomedical ethics assembled by the YODA Project to provide guidance;
● Input from other experts in the ﬁeld, industry, regulators, and the general public through a public
comment period and personal communication;
● Review of the literature and policies from other organizations engaged in clinical trial data sharing,
such as the NIH’s Biologic Specimen and Data Repository Information Coordinating Center
(BioLINCC) within the U.S. National Heart, Lung, and Blood Institute12,13; and
● The experience gained by the YODA Project sharing IPD with external investigators.
www.nature.com/sdata/
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Key Aspects of the YODA Project Data Sharing Policy
There are several key aspects that were considered as decisions were made when establishing the Project’s
data sharing policy. These decisions, and the lessons we learned from their implementation, can be used
to inform and enhance other ongoing or future data sharing initiatives.
Commitment to Transparency. Transparency enhances trust in the integrity of the data sharing
process and the resulting research, as well as clarity of parties involved. To ensure transparency of the
overall effort, the YODA Project makes as much information publicly accessible as possible, including
Project personnel; requirements for data access; information on trial data available, such as Clinical Study
Report summaries and hyperlinks to registration records on ClinicalTrials.gov and publications on
PubMed.gov; information on all submitted proposals for data, such as the number approved and rejected;
and approved research proposals in their entirety, including the resulting research upon completion. In
addition, all major decisions made by the YODA Project have included an opportunity for public
comment, including the ﬁnalized policies and procedures for making clinical trial data available.
Full Authority and Independence. Data sharing requires mutual trust and collaboration with each
partnering company, while at the same time upholding the independence and impartiality of the data-
sharing organization. The YODA Project requires that it has full decision-making authority over the
release of the data and serves as an independent intermediary to manage requests and promote data use.
The ﬁnal decisions regarding the design of the data request process, the criteria for access, and approval
or rejection of requests all reside with the YODA Project. Maintaining this ﬁnal authority is intended to
build trust in the process and reduces opportunities for real or perceived inﬂuence.
Independent Steering Committee. The YODA Project assembled a Steering Committee of external
experts, an independent group of leaders in the ﬁelds of clinical research and biomedical ethics, to
provide guidance as it developed standards, policies, and procedures. The YODA Project was able to call
on the Committee’s expertise to inform the data release process, including how best to make trial
information available, what data request requirements should be established, and what the nature of the
data request review process should be. The Committee also provided valuable feedback on other issues,
such as the importance of making meta-data available (i.e., information about the trials being shared),
including statistical analysis plans, blank case report forms, and study protocols, along with more difﬁcult
issues such as what to do when meta-data materials had not been prepared in English. In addition, the
Committee assisted in making sure that the procedures were consistent with the standards of ethical
research, including avoidance of conﬂict of interest and protection of patient privacy.
List of Available Trials. Publicly listing trials that are available to external investigators is crucial both
to promoting use of the shared data and establishing the transparency of the initiative. However, the
proactive preparation of a catalogue of available trials for a large company with a multitude of marketed
products is time and resource intensive. Therefore, to ensure the efﬁcient use of resources, at the
initiation of our data sharing partnerships, the criteria for deﬁning trials in-scope for sharing were
established. Pertinent to this decision is the protection of patient privacy, as data for which the privacy
and conﬁdentiality of research participants cannot be protected should not be routinely shared, an
important consideration for studies of rare diseases or those that have few participants. Furthermore, for
any product, determinations need to be made as to whether the data are owned solely by the company, as
The YODA Project
Data Request Review Process
Figure 1. The YODA Project data request review process.
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medical products are frequently jointly owned or marketed, requiring consent from both manufacturers
before the data could be shared.
For the partnership with Johnson & Johnson, the number of trials in-scope was large, particularly because of
the company’s commitment to make older trials available. Thus, at the outset, a subset of contemporary trials
for commonly used products likely to be of interest to medical researchers were identiﬁed and publicly listed.
Because this list was not exhaustive of all trials that could be made available, the Project also established a
method for external investigators to inquire about the potential availability of other trials that were not listed.
As additional trials were requested and made available, they were added to the public listing. Further, to
facilitate identiﬁcation of trials by investigators, the listing was organized into multiple views, including by
product, therapeutic area, and condition studied, and also made searchable on key data elements, such as
enrollment and trial demographic characteristics.
Supporting Documentation. In order to increase the likelihood that the data can be used for research,
interested parties need full understanding of the data resources being made available. To this end,
supporting documentation and materials, or meta-data, are described for each available trial, including
hyperlinks to the ClinicalTrials.gov registration (or a number from another international registry) and
known trial publications through PubMed.gov. Similarly, documentation, such as blank case report
forms, clinical study reports, data deﬁnition speciﬁcations, protocols with amendments, and/or statistical
analysis plans, enables investigators to more efﬁciently and accurately determine for what purpose the
data can be best used if access is obtained. Supporting documentation materials made publicly available
are listed in Box 1.
Research Proposal Submission and Public Posting. It is essential to demonstrate that research by
external investigators making use of data made available by industry is responsibly conducted, since
concerns continue to be voiced about the potential for its misuse and misinterpretation6. To promote the
responsible conduct of research, the YODA Project adopted a controlled access model14, requiring
investigator registration and submission of a proposal to be reviewed prior to approval, which can then be
subsequently publicly posted once data access is granted. Speciﬁc information must be submitted,
including the principal investigator, key project personnel, and the research proposal; requirements are
listed in Box 2. Notably, a statistician is not required to be included among key project personnel.
Requiring registration and public posting of proposals potentially fosters collaboration and open science,
while also making it easier for interested independent scientists to evaluate research using shared data.
Blinded Request Review by the YODA Project. All data requests undergo review by multiple clinical
investigator members of the YODA Project, blinded to all identifying details about the investigator,
including funding source. Review helps to ensure that the proposal has scientiﬁc merit, in that 1) the
scientiﬁc purpose is clearly described; 2) the data requested will be used to create or materially enhance
generalizable scientiﬁc and/or medical knowledge to inform science and public health; and 3) the
proposed research can be reasonably addressed using the requested data. The assessment of whether the
proposed research can be reasonably addressed using the requested data includes evaluating whether the
variables needed for the proposed analysis are included in the requested data and whether the question
could best be addressed with either individual participant-level or summary-level data. While the YODA
Project review is not a detailed technical evaluation of the proposed research per se, a high-level review
evaluates whether the proposed statistical methods can answer the scientiﬁc question. The review process
Box 1 | Supporting documentation for each clinical trial made publicly available on the YODA Project webpages.
o Study Title
o Sponsor Protocol Number
o Product Name
o Generic Name
o Therapeutic Area
o Product Class
o Condition(s) Studied
o ClinicalTrials.gov NCT Number and Link to Record
o Link to PubMed Primary Publication Record
o Study Phase
o Enrollment
o Mean/Median Age
o % Female
o % White
o Study Synopsis Link
o Availability (yes/no) of annotated case report forms, data deﬁnition speciﬁcations, protocol with
amendments, analysis datasets, statistical analysis plans, and full clinical study reports
www.nature.com/sdata/
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permits peer-review feedback and/or requests for clariﬁcation prior to approval determination. All
YODA Project reviews are publicly posted.
There have been instances where the YODA Project has also provided feasibility feedback to facilitate
the use of data. For instance, one request was received for a methodological study characterizing trial
populations’ representativeness that would use all trials listed on the YODA Project website (there were
123 at the time); it was determined that preparation of these data would take upwards of 6 months. The
YODA Project communicated this to the investigator, who decided to narrow their proposal to use only
those trials that were already de-identiﬁed and prepared for sharing and planned to subsequently amend
their request as more data became available.
Blinded Request Review by Partnering Company. All data requests undergo a due diligence
assessment by the partnering company, a blinded assessment of whether the data are already prepared or
need to be prepared in a format that is de-identiﬁed and can be made available to external researchers, as
well as whether the variables of interest are available and to check whether a similar analysis is underway
or has already been completed by the company; if so, this information is shared with the investigator. For
example, the YODA Project received a data request that proposed characterizing reasons for trial
eligibility screening failures in late phase trials in advanced genitourinary cancers. After examining the
data, the partnering company advised the YODA Project that reasons for screening failure were not
documented for all occurrences. After relaying this information to the investigator, they still chose to
proceed with their proposal. All company due diligence assessments are publicly posted.
Opportunity for Collaboration with Partnering Company. Data sharing initiatives create a means for
investigators to conduct independent analyses, but they also provide opportunities for new
collaborations.4,15 To foster these collaborations, the YODA Project established a process that allows
for and coordinates communication between investigators and the partnering company, when desired by
the investigator. This process allows external investigators to be made aware of any similar ongoing
research efforts and potentially foster collaboration when there is mutual interest.
Data Use Agreement. All approved data requests require a signed Data Use Agreement (DUA)
between Yale University, representing the YODA Project, and the afﬁliated institution representing the
external investigator. The DUA is intended to ensure that the investigator will protect the conﬁdentiality
of the data, will not attempt to re-identify trial participants, and will not copy, retransmit, or use the data
in any manner other than for the purpose described in the data request. A template is publicly available
for investigators to review prior to requesting data (http://yoda.yale.edu/data-use-agreement). The DUA
limits data access to one year, ensuring frequent updates and contact between the investigators and the
YODA Project, as the agreement can be re-approved for additional time if the research is ongoing. The
DUA also speciﬁes that data cannot be used for non-scientiﬁc purposes, such as in pursuit of litigation or
for commercial interests. While there remains ambiguity in what constitutes non-scientiﬁc use, and
commercial use in particular, the agreement is intended to promote a good faith approach among
researchers. Moreover, the DUA requires investigators to report any notable safety results to the
partnering company, as it is the legal responsibility of any manufacturer of all U.S. Food and Drug
Administration regulated medical products to report these ﬁndings to appropriate regulatory ofﬁcials.
Finally, to ensure that investigators understand the DUA, the YODA Project developed a training module
that must be completed prior to submission of an investigator’s ﬁrst data request, emphasizing important
points and policies governing access.
Secure Data Access or Transfer. The YODA Project has employed two different models of controlled
data access for approved investigators, adopted to ensure the security and prevent wider distribution of
shared clinical trial data. In our partnership with Medtronic, password-protected, de-identiﬁed data were
distributed using secure ﬁle transferring services to approved investigators. Certiﬁcates of data
destruction were required at DUA expiration. This method is not costly and offers greater ﬂexibility to
Box 2 | Information required to be submitted as part of any routine data request.
o Investigator name, afﬁliation, key personnel
o Narrative summary
o Public abstract
o Research proposal, which includes a clear description of the project background, research objectives,
and proposed methods, such as the study design, pre-speciﬁcation of the sample inclusion/exclusion
criteria, main outcome measures and statistical analysis plan
o Conﬂict of interest statement
o Timeline and dissemination plan
www.nature.com/sdata/
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investigators and enables use of additional software types (so long as the investigator has his/her own
license) and linkage to other data sources, but increases the risk of unapproved distribution.
In the YODA Project partnership with Johnson & Johnson, the company entered into licensing
agreements with a secure data sharing platform allowing virtual data access to credentialed and approved
investigators while precluding data download or distribution. While secure, these platforms are expensive
and limited to the licensed analytic tools and software. Moreover, there have been challenges to uploading
complementary or other trial data onto the licensed platform, preventing the combination of data from
different sources, such as for meta-analyses, so that investigators had to rely on the aggregate-level data.
Lastly, users of the platform have also reported it to be difﬁcult to navigate, time intensive to learn, and
noted that the programs occasionally closed, causing loss of work and the user to be logged out.
Nevertheless, on the whole, these platforms have offered a reasonable technical means for data security
and protection against redistribution.
There are certain circumstances that may require access to clinical trial data outside of the secure
platform, such as the need to use proprietary software that cannot be placed in the platform or to pool
data from other sources that cannot access the platform. However, given the sensitivity of patients’ trial
data, including the importance of protecting privacy and risk of re-identiﬁcation, as well as the greater
risk for unauthorized data dissemination and analysis, access outside of the secure platform requires clear
justiﬁcation. In collaboration with Johnson & Johnson, the YODA Project developed an exception request
process, in which the investigator is required to provide additional information to support his/her request
for direct access to the data. This includes 1) strong rationale for why the requested data can uniquely be
used to address the proposed project aims, and reasons why other clinical research data are not available
or cannot be used; 2) reasons why the platform may not permit the proposed analyses; and 3) a
description of the protections in place to ensure data security outside of the platform, including
technological and related procedural safeguards. Based on this information, the YODA Project then
assesses the need for data access outside of the secure platform. Not all exception requests are approved.
Results Dissemination. Upon project completion, the YODA Project requires public dissemination of
research ﬁndings, preferentially through the peer-reviewed biomedical literature or at scientiﬁc meetings.
This explicitly promotes the scientiﬁc process and peer review, ensuring the methods used meet the
minimal scientiﬁc standards prior to dissemination. Once the proposed research has been publicly
disseminated through peer-reviewed publication, these ﬁndings can be further discussed via non-peer-
reviewed forums, including internet posts, newspaper articles, or other means. Regardless of whether the
work is published, all results from analyses are required to be reported back to the YODA Project in
summary form to be publicly posted at the expiration of the DUA, including whether or not the project
was ultimately completed, ensuring public transparency and accountability.
Prior to publication or presentation at a scientiﬁc meeting, copies of any abstract or manuscript generated
from the data request are required to be shared with the YODA Project. This helps to track whether projects are
progressing, clariﬁes what new scientiﬁc information has been generated, and updates our records of the
completion and publication of analyses, informing future data sharing efforts.
Data Access Fee. Thus far, the YODA Project and its data partners have not imposed a fee for
investigators to access data through the YODA Project. The entire cost has been covered by the industry
partners. However, the sustainability of data sharing initiatives, and their current reliance on industry
funding, will likely require reconsideration of funding models, especially given the hope that data sharing
efforts will broaden to include smaller pharmaceutical, medical device, and biotech companies, as well as
academic institutions. A solution may be for investigators to apply for research grants from government
agencies or non-proﬁt organizations to support the use of shared data. Similarly, funding to prepare data
for external sharing should be built into grants awarded to academic groups when they conduct their own
clinical trials. In the current environment, in which funding is already very competitive, whether such
funding models would work is uncertain.
Medtronic Experience
As noted above, Medtronic’s rhBMP-2 clinical trial data were shared once the two independent
systematic reviews and meta-analyses of the data had been published, which occurred in June 201316–18.
Concurrently, an online application process was established and a total of 4 requests for the rhBMP-2
trial data were received. All 4 were approved (additional details, including the protocols, can be found at
http://yoda.yale.edu/medtronic-past-data-recipients), 2 of which were completed and resulted in peer-
reviewed publications19,20. While the rhBMP-2 trial data were generated by a single company, individual
trials did not adhere to the same data formatting and standards, requiring Medtronic to ﬁrst invest
resources into data preparation for sharing, as well as for investigators to review data ﬁles and recode data
as needed to allow aggregation and meta-analysis. The remaining 2 were not completed, both due to
investigator commitments to other projects and lack of time. No instances of data redistribution were
reported and certiﬁcates of data destruction were received for the 2 uncompleted projects; the 2
completed projects retain access to the data for 5 years in the event that questions are raised about their
published analyses, after which time the DUA expires. Because no requests for the data were received
after January 2014, Medtronic discontinued making the data available in summer 2015.
www.nature.com/sdata/
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Total inquiries, No. 161
Total inquiries answered to date, No. (%) 159 (98.8%)
Inquiry led to full data request, No. (%) 31 (19.3%)
Median number of days for response to inquiry (Interquartile Range) 15 (7.5–41.5)
Total unique trials requested within answered inquiries, No. 207
Trial data can be made “available” to request, No. (%) 124 (59.9%)
Trial data cannot be made “available” to request, No. (%) 83 (40.1%)
Regulatory approval not yet received, No. (%) 17 (20.5%)
Trial ongoing or completedo18 months ago, No. (%) 26 (31.3%)
Data cannot be adequately de-identiﬁed, No. (%) 0 (0%)
Partner of Data Holder has not agreed to share, No. (%) 11 (13.3%)
Trial is out of scope (i.e., Phase 1, OTC, etc.), No. (%) 25 (30.1%)
Data subject to partner agreement; researcher advised to contact partnering Data
Holder, No. (%)
2 (2.4%)
Data cannot be converted to electronic format, No. (%) 1 (1.2%)
Trial materials not available in English, No. (%) 5 (6.0%)
Table 1. Details of YODA Project inquiry process for Johnson & Johnson clinical trials as of August
27, 2018.
Trials Available, No. 270
Products Available, No. 31
Trial Enrollment Size
Mean 412.7
Median 322
Min 5
Max 2051
Sex, No. (%)
> 50% Female 101 (37.4%)
≤ 50% Female 131 (48.5%)
[Unknown Sex] 38 (14.1%)
Race, No. (%)
> 50% White 145 (53.7%)
≤ 50% White 26 (9.6%)
[Unknown Race] 99 (36.7%)
Mean/Median Enrollment Age, No. (%)
0–19 24 (8.9%)
20–39 73 (27.0%)
40–59 100 (37.0%)
60+ 32 (11.9%)
[Unknown Age] 41 (15.2%)
Available Data and Documentation, No. (%)
Collected datasets 246 (91.1%)
Analysis datasets 5 (1.9%)
[No participant-level data] 19 (7.0%)
Clinical study report (CSR) 252 (93.3%)
Protocol with amendments 256 (94.8%)
Statistical analysis plan 243 (90.0%)
Annotated case report form 224 (83.0%)
Data deﬁnition speciﬁcation 194 (71.9%)
CSR summary available on site 187 (69.3%)
CSR summary not yet prepared 66 (24.4%)
Table 2. Details of Johnson & Johnson clinical trials available to request as of August 27, 2018.
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Johnson & Johnson Experience
Johnson & Johnson began sharing clinical trial data for all trials of the company’s pharmaceutical
products in October 2014 and later expanded its scope to include trials of medical device and consumer
products. While the company is willing to make all non-Phase I interventional pharmaceutical trials
available, at the initiation of the partnership, we proactively identiﬁed contemporaneous trials likely to be
of greatest interest to the scientiﬁc community and listed them on the YODA Project website. At the same
time, the inquiry process was critical during the early days of the partnership; as of August 2018, 161
inquiries for more than 200 unique trials have been submitted, identifying 124 that could be made
available for sharing (Table 1). Most common reasons for unavailability include that the trial was out-of-
scope (i.e., phase 1 healthy volunteer studies), ongoing or completed less than 18 months ago, or that
regulatory approval had not yet been received (details are available at: http://yoda.yale.edu/request/
summary-data-inquiries-and-requests/details-inquiries-submitted-data-not-yet-available). However, it
should be noted that when investigators inquire about the availability of an out-of-scope trial, they are
invited to submit an abstract that conveys the scientiﬁc importance of the planned research, which is then
evaluated by the YODA Project on a case by case basis; thus far, only 1 investigator has followed up with
an abstract. As of August 2018, 270 clinical trials are listed on the YODA Project website, along with
supporting documentation (Table 2), and additional details, including speciﬁc therapeutic areas (Table 3),
speciﬁc conditions studied (Table 4 (available online only)), speciﬁc products (Table 5), and speciﬁc
product classes (Table 6). Johnson & Johnson started to adopt Clinical Data Interchange Standards
Consortium (CDISC, https://www.cdisc.org/) in 2001 and by 2003 study data sets were being routinely
reported in CDISC format. By using CDISC standards, it brings beneﬁts in enabling the high reuse of
software for data analysis. It also minimizes the time and effort of data preparation before data sharing
can commence. For the researcher, it increases familiarity of data structures and helps to ensure
consistency between trials (and even sponsors).
As of August 2018, 100 data requests have been received from 89 unique principal investigators for a
median of 3 trials per request (Interquartile Range, 1-9), 90 (90.0%) of which have been approved with a
DUA signed or in progress, 2 (2.0%) remain under review pending revision, and 8 (8.0%) were
withdrawn or closed (Table 7). Withdrawals generally occurred because the due diligence assessment
determined that the data needed to address the proposed question were not available (such as requests for
pharmacokinetic data or endoscopic video data) or because special statistical software was needed that
could not be imported into the secure data sharing platform. Notably, two withdrawn requests resulted in
direct collaboration with Johnson & Johnson to pursue the research. No request has been rejected,
although 36 (36.0%) of submitted research proposals required revision after YODA Project review for
clariﬁcation or elaboration, 2 of which were never resubmitted and are now considered withdrawn.
Among the 270 clinical trials currently listed on the YODA Project website, 183(67.8%) have thus far
been requested, although 46 have only been available since January 1, 2018. The most common purposes
of the proposed projects include (not mutually exclusive) addressing secondary research questions (n =
57; 57.0%), combining data as part of larger meta-analysis (n = 45; 45.0%), and validating previously
published studies (n = 24; 24.0%).
Behaviors and Mental Disorders, No. (%) 106 (39.3)
Muscle, Bone, and Cartilage Diseases, No. (%) 26 (9.6)
Digestive System Diseases, No. (%) 23 (8.5)
Cancers and Other Neoplasms, No. (%) 19 (7.0)
Nutritional and Metabolic Diseases, No. (%) 18 (6.7)
Skin and Connective Tissue Diseases, No. (%) 17 (6.3)
Viral Diseases, No. (%) 14 (5.2)
Blood and Lymph Conditions, No. (%) 13 (4.8)
Nervous System Diseases, No. (%) 12 (4.4)
Immune System Diseases, No. (%) 7 (2.6)
Mouth and Tooth Diseases, No. (%) 4 (1.5)
Urinary Tract, Sexual Organs, and Pregnancy Conditions, No. (%) 4 (1.5)
Respiratory Tract (Lung and Bronchial) Diseases, No. (%) 3 (1.1)
Parasitic Diseases, No. (%) 2 (0.7)
Heart and Blood Diseases, No. (%) 1 (0.4)
Neurosciences, No. (%) 1 (0.4)
Table 3. Therapeutic areas of Johnson & Johnson clinical trials available to request as of August 27,
2018.
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Of 82 approved requests provided data access, most remain in progress; 11(13.4%) have at least one
publication21–31 (12 publications in total, see Table 8 for publications list) and 7 (8.5%) have at least one
article under peer-review, whereas 19 (23.2%) have been discontinued, either because of investigator
commitments to other projects and lack of time or because the investigator did not have sufﬁcient
statistical expertise to conduct analyses within the secure data sharing platform. All of the projects that
have been submitted for publication described analyses representing those speciﬁed in the original
research proposal. Finally, no instances of data redistribution have been reported.
Discussion
Data sharing and data transparency are quickly becoming the new standard in pharmaceutical and
medical device science and in clinical research more broadly. Many national and international
organizations are adopting policies to advance scientiﬁc and medical knowledge through data availability
and transparency that will ultimately improve public health and healthcare delivery, advancing scientiﬁc
understanding of disease diagnosis and prognosis through the development of novel tools and
approaches, while also improving existing knowledge of treatment safety and efﬁcacy.
The early experiences of the YODA Project can be used to inform the ﬁeld and other data sharing
initiatives. Certain decisions contrast with other existing clinical trial data sharing initiatives (including
those found at https://biolincc.nhlbi.nih.gov/studies/, https://ClinicalStudyDataRequest.com/, and https://
dcri.org, as examples). For instance, the decision to reactively de-identify data for sharing in response to
requests has meant that 68% of trials listed on the YODA Project website have been used, as opposed to
platforms that have proactively de-identiﬁed data for sharing reporting that approximately 15% of listed
RISPERDAL®, No. (%) 25 (9.3)
INVEGA®, No. (%) 23 (8.5)
TOPAMAX®, No. (%) 22 (8.1)
REMICADE®, No. (%) 21 (7.8)
SIMPONI®, No. (%) 21 (7.8)
RAZADYNE®, No. (%) 20 (7.4)
STELARA®, No. (%) 19 (7.0)
INVOKANA®, No. (%) 13 (4.8)
PROCRIT®, No. (%) 13 (4.8)
CONCERTA®, No. (%) 12 (4.4)
INVEGA SUSTENNA®, No. (%) 11 (4.1)
OLYSIO®, No. (%) 11 (4.1)
RISPERDAL CONSTA®, No. (%) 10 (3.7)
YONDELIS®, No. (%) 10 (3.7)
DARZALEX®, No. (%) 5 (1.9)
Other, No. (%) 5 (1.9)
Mouth Rinse, potassium oxalate 1.4%, No. (%) 4 (1.5)
MONONESSA ® ORTHO-CYCLEN ® ORTHO
TRI-CYCLEN ® TRINESSA ®, No. (%)
3 (1.1)
PREZISTA®, No. (%) 3 (1.1)
DOXIL®, No. (%) 2 (0.7)
EDURANT®, No. (%) 2 (0.7)
PLIVENSIA™, No. (%) 2 (0.7)
Rogaine 5% Women’s Foam, No. (%) 2 (0.7)
SIRTURO®, No. (%) 2 (0.7)
VERMOX®, No. (%) 2 (0.7)
ZYTIGA®, No. (%) 2 (0.7)
INTELENCE®, No. (%) 1 (0.4)
LEVAQUIN®, No. (%) 1 (0.4)
TERAZOL ®, No. (%) 1 (0.4)
THERMOCOOL® SMARTTOUCH™ Catheter,
No. (%)
1 (0.4)
TREMFYA®, No. (%) 1 (0.4)
Table 5. Product names of Johnson & Johnson clinical trials available to request as of August 27,
2018.
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Atypical Antipsychotics, No. (%) 69 (25.6)
Antirheumatic Agents - Biologic Response Modiﬁers, No. (%) 50 (18.5)
Anticonvulsants, No. (%) 22 (8.1)
Alzheimer’s Disease - Cholinesterase Inhibitors, No. (%) 20 (7.4)
Antiviral Agents, No. (%) 17 (6.3)
Antipsoriatics, No. (%) 14 (5.2)
Stimulants/ADHD/Anorexiants, No. (%) 12 (4.4)
Antineoplastic Agents, No. (%) 10 (3.7)
Colony-Stimulating Factors, No. (%) 9 (3.3)
Diabetes Related- Other, No. (%) 9 (3.3)
Monoclonal Antibody, No. (%) 5 (1.9)
Hematologic Agents, No. (%) 4 (1.5)
Mouth Rinse Device, No. (%) 4 (1.5)
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor, No. (%) 4 (1.5)
Immunizations, No. (%) 3 (1.1)
OB/GYN, No. (%) 3 (1.1)
Antimycobacterial Agents, No. (%) 2 (0.7)
Antiparasitics, No. (%) 2 (0.7)
Hormones, No. (%) 2 (0.7)
Oncology - Antibiotic, No. (%) 2 (0.7)
Other, No. (%) 2 (0.7)
Skin & Mucous Membrane Agents, Miscellaneous, No. (%) 2 (0.7)
Cardiovascular Devices, No. (%) 1 (0.4)
Dermatology, No. (%) 1 (0.4)
Quinolones - 3rd gen., No. (%) 1 (0.4)
Table 6. Product class of Johnson & Johnson clinical trials available to request as of August 27, 2018.
Trials Available, No. 270
Trials Shared as Part of Approved Requests, No. (%) 183 (67.8)
Complete Data Requests Received, No. 100
Requests Requiring Revision During Review, No. (%) 36 (36.0)
Purpose of Proposed Research
New research on treatment effectiveness or safety, No. (%) 57 (57.0)
Meta-analysis, No. (%) 45 (45.0)
Validating previous research on treatment effectiveness or safety, No. (%) 24 (24.0)
Research on clinical prediction or risk prediction, No. (%) 20 (20.0)
Develop or reﬁne statistical methods, No. (%) 13 (13.0)
Research on clinical trial methods, No. (%) 12 (12.0)
Preliminary research for a grant proposal, No. (%) 10 (10.0)
Research on comparison group, No. (%) 6 (6.0)
Data Requests Approved, No. (%) 90 (90.0)
Data Requests Under Review, No. (%) 2 (2.0)
Data Requests Withdrawn/Closed, No. (%) 8 (8.0)
Requested data could not be used to address research question, No. 2
Data could not be downloaded as requested by investigator, No. 3
Investigator did not respond to YODA Project request for additional clariﬁcation, No. 2
Investigator withdrew approved request prior to signing DUA due to lack of resources, No. 1
Requests with Data Access [DUA signed by both parties], No. (%) 82 (82.0)
Requests with Publications, No. 11
Table 7. Details of data requests received for Johnson & Johnson clinical trials as of August 27, 2018.
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trials having been used32,33. Similarly, while the direct, secure data transfer used for Medtronic rhBMP-2
trials was simple, the secure platform used for Johnson & Johnson’s trials is more challenging for
investigators, particularly those without advanced statistical expertise. Nevertheless, investigator
experience with this platform mirrors the experience of those using data shared through the U.S.
National Heart, Lung, and Blood Institute BioLINCC repository34. Lastly, Johnson & Johnson makes all
non-Phase I interventional pharmaceutical trials available, including older trials, whereas many current
initiatives and company policies are focused on sharing clinical trial data as of a speciﬁc date going
forward, limiting the availability of trials that examined medical products commonly being used by
patients today.
Outstanding issues remain for the ﬁeld to address, including how to make older trial data available in a
contemporary technology format for use today. Further, a sustainable model that covers the cost of data
sharing is needed, as efforts are currently being paid exclusively by industry and, in some instances, the U.
S. federal government. In addition, while much of the focus on data sharing has thus far been on
industry35,36, many other entities, particularly academia, also generate clinical research data. Lastly, there
is a need going forward for systematic adoption of data format standards37, expectations for how long
shared data will be made available, along with informed consent language, to facilitate data sharing.
Publicly-available informed consent templates that explicitly allow for the sharing of data with external
researchers are already available (http://mrctcenter.org/projects/informed-consent/).
The goal of data sharing initiatives should be to ensure that the data are used to conduct high-quality
and rigorous research that honors the voluntary efforts of patients that participated in the trials and
serves the best interests of science and public health. The research community and society are likely to
greatly beneﬁt from these secondary research efforts. With the continuous advancement of data sharing
efforts, the YODA Project’s experience and the experiences of its ﬁrst two data generator partners,
Medtronic, Inc. and Johnson & Johnson, can be used to enhance other ongoing or future initiatives.
First Author Publication Title Journal Year Publication ID Cited by:
Fu, R Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine
fusion: a systematic review and meta-analysis.
Ann Intern Med 2013 doi:10.7326/0003-4819-
158-12-201306180-00006
299
Simmonds, MC Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal
fusion: a meta-analysis of individual-participant data.
Ann Intern Med 2013 doi:10.7326/0003-4819-
158-12-201306180-00005
233
Laurie, AL Meta-analysis of the Impact of Patient Characteristics on Estimates of Effectiveness and
Harms of Recombinant Human Bone Morphogenetic Protein-2 in Lumbar Spinal
Fusion.
Spine 2016 doi:10.1097/
BRS.0000000000001580
3
Noshchenko, A What Is the Clinical Relevance of Radiographic Nonunion After Single-Level Lumbar
Interbody Arthrodesis in Degenerative Disc Disease? A Meta-Analysis of the YODA
Project Database.
Spine 2016 doi:10.1097/
BRS.0000000000001113
5
Mospan, GA 5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary
Tract Infection (UTI).
J Am Board Fam Med 2016 doi:10.3122/
jabfm.2016.06.160065
4
Storgaard, H Beneﬁts and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with
Type 2 Diabetes: A Systematic Review and Meta-Analysis.
PLoS One 2016 doi:10.1371/journal.
pone.0166125
37
Gay, HC Feasibility, Process, and Outcomes of Cardiovascular Clinical Trial Data Sharing: A
Reproduction Analysis of the SMART-AF Trial.
JAMA Cardiol 2017 doi:10.1001/
jamacardio.2017.3808
6
Corbett, M Certolizumab pegol and secukinumab for treating active psoriatic arthritis following
inadequate response to disease-modifying antirheumatic drugs: a systematic review and
economic evaluation.
Health Technol Assess 2017 doi:10.3310/hta21560 4
Mbuagbaw, L Review of available evidence on the use of bedaquiline for the treatment of multidrug-
resistant tuberculosis: Data analysis report; Appendix to A 2016 review of available
evidence on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis.
World Health
Organization
2017 Report No. WHO/HTM/
TB/2017.01
2
Wang, R Comparative Efﬁcacy of Tumor Necrosis Factor-alpha Inhibitors in Ankylosing
Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
J Rheumatol 2018 doi:10.3899/
jrheum.170224
1
Schneider-Thoma J Second-generation antipsychotic drugs and short-term mortality: a systematic review
and meta-analysis of placebo-controlled randomised controlled trials.
Lancet Psychiatry 2018 doi: 10.1016/S2215-0366
(18)30177-9
1
Singh, S Impact of Obesity on Short- and Intermediate-Term Outcomes in Inﬂammatory Bowel
Diseases: Pooled Analysis of Placebo Arms of Inﬂiximab Clinical Trials.
Inﬂamm Bowel Dis 2018 doi:10.1093/ibd/izy135
Singh, S No Beneﬁt of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis
Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From
Clinical Trials.
Am J Gastroenterol 2018 doi:10.1038/s41395-018-
0144-2
Singh, S Obesity and Response to Inﬂiximab in Patients with Inﬂammatory Bowel Diseases:
Pooled Analysis of Individual Participant Data from Clinical Trials.
Am J Gastroenterol 2018 doi:10.1038/s41395-018-
0104-x
Zou, X The role of PANSS symptoms and adverse events in explaining the effects of
paliperidone on social functioning: a causal mediation analysis approach.
NPJ Schizophrenia 2018 doi:10.1038/s41537-018-
0054-8
Spertus, J Risk of weight gain for speciﬁc antipsychotic drugs: a meta-analysis. NPJ Schizophrenia 2018 doi:10.1038/s41537-018-
0053-9
Table 8. Publications using data made available through the YODA Project.
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Methods
We provide an overview of the history of the YODA Project, including a review of the policy and
procedures iteratively developed to guide granting qualiﬁed public access to clinical trial data provided by
partnering data generators. We base the review on the experience with the ﬁrst two partners in the
Project, Medtronic, Inc. and Johnson & Johnson. This policy and set of procedures address the research
proposal requirements, data receipt, data analysis, and dissemination of results (http://yoda.yale.edu/
policies-procedures-guide-external-investigator-access-clinical-trial-data). Speciﬁcally, the policy guides
the procedures that are used to make clinical trial data (including both Clinical Study Reports [CSRs] and
participant-level trial data) available to external investigators for independent scientiﬁc examination. Key
aspects of the policy and the underlying decisions were informed by the following:
● The YODA Project’s core principles of fairness and transparency;
● The YODA Project’s review of the literature and policies from other organizations engaged in clinical
trial data sharing;
● Recommendations from the YODA Project Steering Committee, an independent group of leaders in
the ﬁelds of clinical research and biomedical ethics assembled by the YODA Project to provide
guidance;
● Recommendations from other experts in the ﬁeld, general public, and industry partners through a
public comment period and personal communication; and
● The YODA Project’s accumulated experience with sharing participant-level clinical trial data.
Where appropriate, descriptive statistics were used to characterize the status of data requests and
approvals.
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